CPT1B Antibodies

Carnitine O-palmitoyltransferase 1, muscle isoform (CPT1B)

Gene Information

Human
Gene Name:	CPT1B
Uniprot:	Q92523
Entrez:	1375

Family

Belongs to:
carnitine/choline acetyltransferase family

Alternative Names

carnitine O-palmitoyltransferase 1, muscle isoform; carnitine O-palmitoyltransferase I, mitochondrial muscle isoform; Carnitine O-palmitoyltransferase I, muscle isoform; carnitine palmitoyltransferase 1B (muscle); Carnitine palmitoyltransferase 1B; Carnitine palmitoyltransferase I-like protein; CPT I; CPT1M; CPT1-MMCCPT1; CPTI; CPTI-M; EC 2.3.1; EC 2.3.1.21; FLJ55729; FLJ58750; KIAA1670; MCPT1; M-CPT1

Molecular Weight

Mass (kDA):
87.801 kDA

Genomic Context

Human
Location:	22q13.33
Sequence:	22; NC_000022.11 (50568861..50578612, complement)

Tissue Specificity

Strong expression in heart and skeletal muscle. No expression in liver and kidney.

Subcellular Localizations

Mitochondrion outer membrane; Multi-pass membrane protein.

Diseases

• Obesity
• Insulin Resistance
• Diabetes Mellitus
• Narcolepsy
• Cataplexy
• Impaired Glucose Tolerance
• Diabetes Mellitus, Non-insulin-dependent
• Hypertrophy
• Sleep Disorders
• Cardiovascular Diseases
• Cardiac Hypertrophy
• Malignant Neoplasms

• Hyperinsulinism
• Diabetes Mellitus, Experimental
• Inflammation
• Insulin Sensitivity
• Essential Hypertension
• Excessive Daytime Somnolence
• Hypoxia

Interacting Proteins

• TEX44

Pathways

• Fatty Acid Oxidation
• Lipid Oxidation
• Transport
• Energy Homeostasis
• Gluconeogenesis
• Fatty Acid Transport
• Aging
• Fertilization
• Protein Secretion
• Developmental Maturation
• Embryo Development
• Glucose Homeostasis
• Carnitine Transport

• Reverse Transcription
• Blastocyst Development
• Regulation Of Fatty Acid Oxidation
• Lipid Storage
• Regulation Of Energy Homeostasis
• Cell Proliferation
• Lactation

PTMs

• Oxidation
• Sumoylation

• Demethylation
• Phosphorylation

• Methylation

Research Areas

• Lipid and Metabolism

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/CPT1B

Best Uses Of The CPT1B Marker

One of the main antibodies Boster produces is a great option for those looking for antibodies that target CPT1B. Many of their antibodies have been awarded high numbers of citations in scientific journals over the past 25 years. Furthermore, they have been validated using Western Blotting, Immunohistochemistry, and ELISA. Utilizing a high-affinity primary antibody will guarantee the highest level of quality that is an essential aspect of research.

CPT1B Marker interfered with the beneficial effect of flavonoid

Obesity is a significant health issue in the world and is linked to increased death rates and health care costs. Metabolic disorders are a result of obesity, which is a problem with metabolism of fat. Quercetin, a flavonoid, a secondary plant metabolite, is a plant-based phytochemical that has anti-inflammatory as well as anti diabetic effects. Researchers are currently searching for ways to boost the effectiveness of the flavonoid, and reduce the risk of metabolic diseases and obesity.

In addition quercetin, an antioxidant, has been proven to interfere with the effects of metabolism on acetaminophen, a common pain reliever. The metabolic interactions of quercetin have been investigated with paracetamol (acetaminophen). In a prior study, the flavonoid Lutein was discovered to interfere with the drug's beneficial effects. It also inhibited enzymes in the metabolism of quercetin like glutathione transferase or aldo-keto reduce.

Additionally the researchers behind the study also concluded that Boster Bio CPT1B Marker interfered with the effects of flavonoid on rats. The results of this study were published in the Journal of Nutrition in 2007. Rinaldi and Schmidt, Thomas, Schmidt, Thomas, Situ, Alan J., and Johnson, Janet O. were the researchers.

Baicalin as a pharmacological therapy for DIO

Obesity is a global epidemic. Many suffer from metabolic illnesses that could cause increased mortality as well as significant health care costs. Baicalin is a novel pharmacological treatment for DIO that exhibits antisteatosis activity by targeting carnitine palmitoyltransferase-1 (CPT1). Baicalin activates the hepatic CPT1 and stimulates the infusion of lipids into mitochondria. Baicalin treatment over time can help reduce the steatosis of the liver as well as the diet-induced obesity and leads to a systemic improvement in metabolic disorders.

The anti-inflammatory properties of Baicalein are crucial since it decreases the stress of oxidative, which can result in a variety digestive diseases. Baicalein and its metabolite wogonoside have been shown to have anti-inflammatory properties. These properties may be the reason why baicalin can be used as a pharmacological treatment for DIO. However, further research is required to confirm baicalein's effect on the immune system.

The extracts of Scutellaria Radix have been used in traditional Chinese medicine for centuries. Baicalin is the active ingredient in these extracts inhibits nitric oxygen synthase and activates nuclear factor KappaB. It also inhibits adipogenesis. Baicalin also blocks the expression certain genes that are involved in the process of adipogenesis.

Baicalin was found to be a useful pharmaceutical treatment for DIO in numerous studies. Baicalin is a natural antioxidant that has anti-inflammatory effects. It can also protect neurons from the effects of apoptosis by preventing it. Although the results are encouraging but further research is needed to determine the proper dosage. Baicalin may have many benefits.

Baicalin is a potential drug therapy for DIO. It also offers numerous other benefits, such as relaxation and stress relief. Baicalin could help manage the primary symptoms of ADHD by increasing brain DA levels. Baicalin also offers neuroprotection, memory enhancement, and antiviral/antibiotic activities. However, many of these benefits can be attributed to animal research and further research is required in order to determine if baicalin may be beneficial for treating DIO in humans.

Recombinant UBGT was found to catalyze the reaction between UDP-glucose as well as baicalein in the course of a randomized trial. High-performance liquid chromatography has identified the substance, authentic baicalein-7O-glucoside. This recombinant enzyme has activities towards flavonoids, kaempferol and phenolic compounds. Furthermore, it builds up in hairy roots after treatment with salicylic acid or other treatments.

Potential uses for CPT1B marker

The potential applications for the CPT1B Marker in biomedical research are numerous. This enzyme is involved in fatty acid metabolism as well as PPAR pathways. Researchers believe that CPT1B may play a role in the pathophysiology and treatment of PTSD. A new assay for gene expression is helping to make this discovery. Researchers are also investigating the potential uses of the CPT1B Marker for blood.

Recent studies have shown that overexpression of the CPT1B gene increases insulin resistance in rats as a model. CPT1B gene overexpression in skeletal muscle cells improves insulin resistance, and also increases mitochondrial flexibility. Furthermore, age-related CPT1B degeneration could contribute to the accumulation of lipids. The CPT1B gene is a critical factor in the flexibility of mitochondria. Studies in mice have shown that the CPT1B gene activity decreases with age.

Previous research has demonstrated that the expression of CPT1B in prostate cancer is associated with poor survival in the absence of disease. Additionally, removing the CPT1B gene slowed cell proliferation, reduced S-phase distribution, and decreased the ability to invade. Further research has revealed that DEGS is associated with calcium Ion binding. This suggests that the gene could be controlled by AR. Dual luciferase tests were used to confirm that the gene was expressed in the cancer cells.

In vivo, the regulation of CPT1B's activity is predicted to remain in close proximity to one throughout a wider range of palmitoyl-CoA levels. Simulated experiments also revealed that malonyl CoA's actions are crucial in regulating the CPT1B activity. Age-related mice showed significant remodeling of b-oxidation protein, while aged animals had reduced flexibility at CPT1B.

Currently, the CPT1B genes are the dominant one in neonatal heart. When mice with CPT1b deficiency undergo TAC-induced LV pressure overload, their activity decreased by 70% compared with mice with WT. Furthermore, an echocardiographic analysis of CPT1b-/ mouse revealed similar anatomic structure and function. The measurements of the working heart were not affected.